Bacteriotal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bacteriotal

Property Description
Active Ingredient Norfloxacin
Form Film-coated tablet (Oral), Ophthalmic solution (Topical)
Pharmacological Class Fluoroquinolone Antibiotic (Second-Generation)
Common Therapeutic Use Anti-infective therapy against bacterial pathogens
Origin Synthetic Compound

What Type of Medicine is Bacteriotal (Norfloxacin)?

Bacteriotal is a strictly prescription-only medicine (Rx) classified as a potent synthetic antibacterial agent, containing the sole active ingredient of Norfloxacin. This agent is specifically categorized as a second-generation fluoroquinolone, placing it within a potent class of quinolone antibiotics used for anti-infective therapy. The Norfloxacin compound is recognized as an effective broad-spectrum antimicrobial and is included on the Model List of Essential Medicines. It is formulated as a single-component product, primarily presented as an oral film-coated tablet intended for systemic action, although it is also available in some regions as an ophthalmic solution for topical use. This classification confirms its defined role as a drug designed to target and resolve underlying bacterial infections across various body systems.


Composition and Origin: Is Norfloxacin Synthetic?

Norfloxacin is a chemically-defined, completely synthetic compound manufactured in a laboratory, meaning it is not derived from biological sources. This synthetic compound is characterized by its precise quinolone structure, which includes a critical fluorine atom that enhances its effectiveness and bactericidal activity. This composition is central to its mechanism of effect, where it directly interrupts the replication machinery of bacteria by inhibiting key enzymes, a mechanism recognized for its action against susceptible pathogens. The medicine's general therapeutic purpose, therefore, is to provide a strong defense against microbial disease by actively killing the bacterial pathogens responsible for causing various systemic infections in adult patients.

What side effects are possible with Bacteriotal?

Possible side effects and safety information

The safety profile for Bacteriotal (Norfloxacin) is formally categorized by regulatory bodies, detailing documented adverse reactions and specific safety constraints. Reactions are grouped by their incidence and the physiological system they affect.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Common Nausea, headache, dizziness, insomnia, and elevated liver enzymes.
Uncommon Anxiety, depression, blurred vision, fever, and anorexia.

Serious Adverse Reactions and Systemic Concerns

The official labeling highlights potentially disabling and irreversible adverse reactions affecting multiple systems. These include severe events within the Musculoskeletal and Connective Tissue systems, such as tendinitis and tendon rupture (often affecting the Achilles tendon), and the Nervous System, encompassing peripheral neuropathy (tingling, numbness, pain) and seizures.

Further serious reactions documented include effects on the Cardiac system, specifically QTc interval prolongation and the risk of Torsades de Pointes, and the documented risk of Aortic Aneurysm and Dissection.

Safety Constraints and Population Notes

The drug is associated with time-related patterns, where serious effects like tendon damage may occur within 48 hours of starting treatment or be delayed for several months after discontinuation, and neurological symptoms may be long-lasting. Safety notes identify certain populations with increased risk, including older adults, organ transplant recipients, and patients with renal impairment. Official restrictions also apply, such as caution with concomitant corticosteroid use and avoidance in patients with a history of Myasthenia Gravis.

Overdose and Emergency Response

The official regulatory profile for Norfloxacin, the active ingredient in Bacteriotal, defines the documented clinical manifestations that may occur following an overdose. These presentations include specific gastrointestinal disturbances such as vomiting, diarrhoea, and in severe situations, gastrointestinal haemorrhage. Neurological signs like dizziness, tinnitus, and the risk of convulsions are also explicitly documented. The profile alerts that a state of significant poisoning carries the potential for severe, life-threatening systemic outcomes, including the documented development of acute renal failure and liver damage.

The governmental labeling mandates that individuals call a healthcare provider immediately or get medical help immediately upon suspecting an overdose. Management is limited to supportive measures because no specific antidote is known. Officially described procedural steps may include symptomatic and supportive treatment, gastric decontamination (such as gastric lavage), and potentially the use of forced diuresis to aid elimination. Observation for crystalluria and monitoring for the progression of acute renal failure or liver damage is required. This profile exclusively addresses the documented signs and mandated actions, providing a clear regulatory framework for emergency response.

Therapeutic Uses of Bacteriotal

What Bacteriotal Treats: Main Uses and Benefits

Bacteriotal is commonly used in situations involving certain distressing symptoms across key therapeutic domains, generally focusing on the genitourinary and gastrointestinal tracts. It is considered relevant for managing acute bacterial infections of the urinary tract (including cystitis and prostatitis) and certain forms of bacterial gastroenteritis and traveler's diarrhea. It is also applied in addressing localized ocular infections and provides supportive relief in preventing specific severe bacterial infections in high-risk patient groups.

Managing Symptom Domains

Bacteriotal is commonly used to help manage acute and recurrent bacterial infections. It addresses symptom clusters that may become intense or disruptive, such as painful or burning urination (dysuria) and urgency related to UTIs, or severe diarrhea and abdominal cramping linked to enteric infections. Applied in clinical settings that involve acute or unstable symptom patterns, its use offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load. For high-risk patients, it provides supportive relief in preventing specific severe bacterial infections.

“The use of the medicine helps maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Dysuria

Quick Fact: Relief for Dysuria (painful urination) is generally experienced when managing lower urinary tract infections, supporting patients during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Official Eligibility Rules for Bacteriotal (Norfloxacin)

The use of Bacteriotal is strictly defined by regulatory documents, which establish the official eligible population and several absolute exclusions.


Populations For Whom Use is Contraindicated

Bacteriotal must not be used by specific groups due to formal regulatory contraindications:

  • Patients with a known hypersensitivity or allergy to Norfloxacin or any other medicine in the quinolone class.
  • Individuals with a history of tendon rupture or tendinitis associated with prior quinolone use.
  • Children and growing adolescents in whom safety and efficacy have not been established.
  • Pregnant or breastfeeding women.
  • Patients with Myasthenia Gravis.

Populations Requiring Conditional Use

Use is permitted only under specific regulatory restrictions for certain adult groups:

  • Severe Renal Impairment: Eligibility is conditional on a modified, adjusted dosage being administered.
  • CNS Disorders: Patients with conditions like epilepsy must only use the medicine if the benefit is officially judged to clearly outweigh the risk.
  • Older Adults: Use requires caution due to a documented increased risk of tendon problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Bacteriotal (Norfloxacin) is structured by pharmacokinetic, pharmacodynamic, and chelation-based constraints documented in regulatory labeling.

Interaction Type Interacting Agent Examples Regulatory Outcome
Exposure Modification (CYP1A2) Theophylline, Caffeine, Clozapine Norfloxacin is documented as a CYP1A2 inhibitor, leading to increased plasma concentrations of these agents.
Absorption Interference (Chelation) Antacids (Mg/Al), Iron/Zinc supplements, Sucralfate Requires mandatory timing separation as metal cations bind to Norfloxacin, significantly reducing its absorption.

Interaction-Related Restrictions

Formal labeling advises against or restricts several combinations due to increased risk. Co-administration of Class IA or III Antiarrhythmics should be avoided due to the heightened risk of QTc prolongation. The use of Corticosteroids is officially restricted because it increases the danger of tendon injury or rupture. The combination with Nitrofurantoin is not recommended as it may antagonize Norfloxacin's antibacterial activity.

Other Clinically Relevant Interactions

Norfloxacin may enhance the effects of oral anticoagulants like Warfarin, necessitating close monitoring. Use with NSAIDs may increase the risk of CNS stimulation. The separation requirement for cation-containing products and milk/dairy products is at least two hours to ensure adequate Norfloxacin absorption. This heightened tendon risk with corticosteroids is noted in labeling as being greater in older patients and those with renal impairment.

Mechanism of Action

Bacteriotal (Norfloxacin) is classified as a bactericidal agent, meaning its mechanism is defined by the direct destruction of susceptible bacterial cells. This action is rooted in the targeted and highly specific inhibition of two bacterial enzymes essential for genetic function: DNA Gyrase (Topoisomerase II) and Topoisomerase IV.

The drug acts by non-covalently trapping these enzymes in an intermediate state where the bacterial DNA has been cut but not resealed (the cleavage complex). This stabilization triggers a lethal mechanistic cascade, leading to the rapid accumulation of irreparable DNA double-strand breaks within the cell. This genomic damage overwhelms the bacterial cell’s repair systems, resulting in catastrophic cellular destruction and a resulting reduction of the viable microbial population.

Functionally, this mechanism is constrained by bacterial defenses. Impairment results when point mutations occur in the genes encoding the target enzymes (GyrA or ParC), or when overactive efflux pumps expel the Norfloxacin molecule, preventing the high intracellular concentration required to execute the full bactericidal action at the target sites.

Dosage and Administration Information

Official Administration Guidelines

Bacteriotal (Norfloxacin) is officially administered via two distinct approved routes: the 400 mg oral film-coated tablet for systemic action, and a 0.3% concentration for topical ocular use in certain jurisdictions. The usage protocol is structured around adherence to specific dosing and timing requirements.


Dosing and Frequency

The standard adult systemic dosing regimen is 400 mg taken every 12 hours (twice daily). Treatment duration is variable, ranging from a 3-day course for certain uncomplicated infections to 28 days for chronic bacterial prostatitis, based on the approved indication. For specific, limited indications, a single 800 mg dose may be utilized.


Procedural Requirements

A crucial instruction for the oral tablet is the time-relationship to food and supplements. The tablet must be taken on an empty stomach, specifically at least one hour before or two hours after consuming meals, milk, or dairy products. Co-administration with products containing mineral ions—such as antacids, iron, or zinc supplements—requires a two-hour separation from the Bacteriotal dose. The film-coated tablet must be swallowed whole and not chewed or crushed.

Population Adjustment

For adult individuals with significantly impaired kidney function (creatinine clearance leq 30 mL/min), the labeled frequency is reduced to 400 mg once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bacteriotal (Norfloxacin)

The research base for Bacteriotal (Norfloxacin) includes data from Randomized Controlled Trials (RCTs) and supporting reviews, as documented by regulatory bodies and peer-reviewed scientific literature. This overview describes what clinical research has explored and what the findings suggest, using neutral language.


Evidence for Use in Acute Urinary Tract Infections (UTI) and Prostatitis

Norfloxacin was studied for acute bacterial infections of the urinary tract and prostate in non-pregnant adult patients. Research monitored two main outcomes: Bacteriological Eradication (pathogen clearance) and the primary endpoint of Clinical Cure (resolution of symptoms, such as painful urination). Studies reported measurements of clearance and symptom resolution.

Research on Complicated vs. Uncomplicated UTIs

Research for uncomplicated UTIs generally has an Evidence quality described as High. For complicated UTIs and prostatitis, studies involved more heterogeneous populations and longer treatment periods. For these complex contexts, Evidence quality varies across studies, leading to a moderate certainty classification.


Evidence for Use in Bacterial Gastroenteritis and Traveler’s Diarrhea

Norfloxacin was evaluated in short-term comparative trials for bacterial gastroenteritis and traveler’s diarrhea. Researchers examined outcomes related to systemic imbalance, such as the frequency and duration of severe diarrhea. Findings describe patterns observed in the studies that include data on the duration of acute symptom activity, though results apply only to the populations studied and are not generalizable across all regions.


Evidence for Topical Use in Ocular (Eye) Infections

For ocular infections (eye drops), research examined its local effects. Outcomes monitored included the primary endpoint of Microbiological Eradication and reduction in physical signs. The research provides insight into short-term changes over a very short observation period. Since the use is topical, there is limited information available regarding any systemic or body-wide effects.


Long-Term Data, Recurrence Rates, and Follow-up Durations

Most clinical trials have follow-up durations that were limited to a few weeks or months post-treatment. Consequently, long-term effects are not fully established or well characterized over periods exceeding six months to a year. Research provides context, but not individual predictions regarding recurrence over extended timeframes.


Evidence in Specific Patient Populations and Gaps

The majority of pivotal research was evaluated in healthy, non-pregnant adult patients. Data for certain groups remain insufficient, such as the pediatric population (children); the lack of comprehensive evidence in this group is a documented limitation. Additionally, the increasing global prevalence of antibiotic resistance means that older research findings may not perfectly reflect the current clinical context, and comparative evidence is lacking for some of the newer treatment options.

Key Studies & References World Health Organization Model List of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Bacteriotal (FAQ)

Q: What are the most commonly reported side effects of Bacteriotal?

Official drug documents often list adverse reactions by how often they occur. Commonly reported events associated with the active ingredient (Norfloxacin) often include reactions such as headache, dizziness, nausea, and diarrhea.

Less common, more serious reactions are described in the official warnings section of the product information.


Q: What happens if I accidentally take two doses of Bacteriotal close together?

If more than the intended amount of Bacteriotal is taken, seeking immediate medical attention is described as necessary by regulatory sources.

While official documents do not provide detailed patient instructions for this specific scenario, they generally describe potential symptoms of an overdose, which may include effects like tremors, disorientation, or slurred speech.


Q: Does Bacteriotal make you more sensitive to the sun?

Yes, regulatory labeling indicates that the active ingredient in Bacteriotal belongs to a class of drugs associated with photosensitivity or phototoxicity reactions.

This can appear as an exaggerated or severe sunburn reaction. Official warnings advise limiting or avoiding sun exposure and artificial ultraviolet (UV) light while taking this medication.


Q: Does Bacteriotal interact with any common foods?

Official information states that the absorption of Bacteriotal is significantly reduced when it is taken with dairy products (like milk or yogurt).

Therefore, a time separation of at least two hours is required by official administration guidelines between taking Bacteriotal and consuming dairy products.


Q: Is it possible to be allergic to Bacteriotal?

Official labeling notes that the drug is contraindicated (should not be used) in people with a known history of hypersensitivity or allergic reactions to the drug or other quinolone antibiotics.

Serious, and occasionally fatal, hypersensitivity reactions are reported in official warnings for this class of medication.


Q: Why does the official leaflet mention potential liver issues with Bacteriotal?

Regulatory sources and official medical literature have noted rare instances of acute liver injury linked to norfloxacin, the active ingredient.

Symptoms such as unexplained dark urine, persistent abdominal pain, or a yellowing of the skin or eyes (jaundice) are noted as potential signs of liver issues in official documents.


Q: Are there specific symptoms that mean Bacteriotal is not working?

Effectiveness in clinical trials is often measured by endpoints like 'Clinical Cure,' which refers to the resolution of symptoms.

If the original symptoms of the infection (such as fever, pain, or discomfort) persist or worsen after several days of treatment, it may indicate that the infection is not responding as expected.


Q: How long does it usually take to feel the effects of Bacteriotal?

Pharmacokinetic studies show that the medication reaches its peak concentration in the bloodstream about one to two hours after a dose is taken.

However, the timeline for symptom improvement and clinical recovery can vary depending on the specific type and severity of the condition being treated.


Q: Can Bacteriotal cause weight gain?

Weight gain is not listed among the commonly reported side effects of Bacteriotal in official documents.

In adverse event listings, both weight gain and unexplained weight loss have been noted in the categories for rare or infrequently reported events.


Q: What should I do if I miss a dose of Bacteriotal?

Regulatory patient information typically describes the protocol for a missed dose, which involves taking it as soon as it is remembered.

If it is almost time for the next dose, the guidance described is to skip the missed dose entirely and resume the normal schedule.


Q: Is Bacteriotal safe to take with common pain relievers like ibuprofen?

Official labeling advises caution when using Bacteriotal alongside non-steroidal anti-inflammatory drugs (NSAIDs), which includes common pain relievers like ibuprofen.

The combination may increase the risk of Central Nervous System (CNS) stimulation, including convulsions.


Q: What are the long-term safety concerns associated with Bacteriotal?

Warnings in regulatory documents include the risk of disabling and potentially irreversible adverse reactions associated with this class of drugs.

These can include tendinitis, tendon rupture, and peripheral neuropathy (nerve damage) in the arms and legs.


Q: Are there different brand names for the medicine in Bacteriotal?

The active ingredient in Bacteriotal is Norfloxacin.

Official documents in different regions list various trade names, such as Noroxin, in addition to generic formulations of the same active ingredient.


Q: Do I need to take Bacteriotal with food?

No, official administration guidelines specify that the oral tablet must be taken on an empty stomach.

Regulatory guidelines state it must be taken either at least one hour before a meal or two hours after a meal.


Q: Is Bacteriotal a controlled substance?

According to the US Drug Enforcement Administration (DEA) and similar international bodies, norfloxacin is not classified as a controlled medication.

It is available as a prescription drug but is not subject to the heightened restrictions placed on controlled substances.


Q: Can Bacteriotal be crushed or split if it's hard to swallow?

No, official procedural requirements state that the film-coated tablet must be swallowed whole with fluid.

Regulatory warnings advise against chewing, crushing, or splitting the tablet before consumption.


Q: What is the chemical name of the active ingredient in Bacteriotal?

The common, non-proprietary name for the active ingredient is Norfloxacin.

Its systematic chemical name, as defined in regulatory documents, is 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid.


Q: Does Bacteriotal affect sleep patterns?

The product information notes that sleep-related issues can occur, though they are not common.

Adverse event listings include reports of both insomnia (difficulty sleeping) and sleepiness, among other Central Nervous System (CNS) effects.


Q: What kind of research has been done on Bacteriotal in children?

The safety and effectiveness of the active ingredient (Norfloxacin) in pediatric patients (individuals under 18 years of age) have not been established.

The product label specifies that it is not approved for use in this population due to a lack of comprehensive evidence.


Q: Can I use alcohol while I'm taking Bacteriotal?

Official labeling is typically silent on specific alcohol contraindications with norfloxacin.

However, caution is often generally advised with medications that can cause side effects like dizziness or interfere with the body's recovery from illness.


Q: How does the body eliminate Bacteriotal?

The majority of Bacteriotal and the substances it breaks down into (metabolites) are eliminated from the body through the urine via the kidneys and, to a lesser extent, through the feces.

This process is formally described in the Pharmacokinetics section of the product information.


Q: Is Bacteriotal effective for minor infections?

Bacteriotal is indicated for specific approved uses, such as uncomplicated urinary tract infections (UTIs) and Traveler's Diarrhea, among others.

These indications define the range of infections the drug is officially intended and approved to treat.


Q: What kind of patient monitoring is typically advised during Bacteriotal treatment?

Official labeling notes that monitoring may be advised in certain situations, such as when the drug is used with other medications that affect coagulation or blood sugar.

Examples include monitoring coagulation tests (like PT/INR) for people taking blood thinners and monitoring blood sugar for people taking certain anti-diabetes medications.


Q: Can I stop taking Bacteriotal as soon as I feel better?

Patient information emphasizes that the entire prescribed course of treatment must be fully completed.

Completing the full prescribed duration is noted in official information to help ensure the infection is completely treated and to support efforts against antibiotic resistance.

How should Bacteriotal be stored and disposed of?

How to Store and Dispose of Bacteriotal?

The storage conditions for Bacteriotal (Norfloxacin) vary by formulation, as specified in regulatory documentation.


Storage Requirements

Formulation Mandatory Temperature In-Use Stability Constraint
Oral Tablets Controlled room temperature (20 C to 25 C) Store in a tightly closed container
Ophthalmic Solution Room temperature (below 30 C) Must be discarded 4 weeks after opening

Both forms must be protected from moisture and light, and they must be kept out of the sight and reach of children.

️ Disposal Instructions

The preferred method for disposing of unused or expired Norfloxacin is through an official drug take-back program. The medication must not be flushed down the sink or toilet. If a take-back program is unavailable, the drug should be mixed with an unpalatable substance (like coffee grounds), sealed in a bag, and disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bacteriotal found in:

A-Z Index: